Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samit Hirawat

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Cancer Investigation|August 7, 2003
The androgen receptor: structure, mutations, and antiandrogensSamit Hirawat, Daniel R Budman, Willi Kreis
Annals of the New York Academy of Sciences|April 5, 2013
Challenges in the clinical development of PI3K inhibitorsCristian Massacesi, Emmanuelle di Tomaso, Nathalie Fretault, et al.
Annals of Clinical and Laboratory Science|May 23, 2002
Langerhans' cell histiocytosis in the parotid glandFarbod Darvishian, Samit Hirawat, Saul Teichberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2008
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse modelMing Du, Xiaoli Liu, Ellen M Welch, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2006
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumorsHerbert I Hurwitz, Roger B Cohen, J Patrick McGovren, et al.
Cancer Investigation|May 29, 2007
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabineSamit Hirawat, Jonathan Kolitz, Stuart M Lichtman, et al.
Oncotargets and Therapy|January 22, 2016
PI3K inhibitors as new cancer therapeutics: implications for clinical trial designCristian Massacesi, Emmanuelle Di Tomaso, Patrick Urban, et al.
Muscle & Nerve|November 27, 2009
The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophyCraig M McDonald, Erik K Henricson, Jay J Han, et al.
Journal of Clinical Pharmacology|March 29, 2007
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteersSamit Hirawat, Ellen M Welch, Gary L Elfring, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein TranslationMarla Weetall, Thomas Davis, Gary Elfring, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Cancer Investigation|August 7, 2003
The androgen receptor: structure, mutations, and antiandrogensSamit Hirawat, Daniel R Budman, Willi Kreis
Annals of the New York Academy of Sciences|April 5, 2013
Challenges in the clinical development of PI3K inhibitorsCristian Massacesi, Emmanuelle di Tomaso, Nathalie Fretault, et al.
Annals of Clinical and Laboratory Science|May 23, 2002
Langerhans' cell histiocytosis in the parotid glandFarbod Darvishian, Samit Hirawat, Saul Teichberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 2008
PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse modelMing Du, Xiaoli Liu, Ellen M Welch, et al.
Cancer Chemotherapy and Pharmacology|July 5, 2006
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumorsHerbert I Hurwitz, Roger B Cohen, J Patrick McGovren, et al.
Cancer Investigation|May 29, 2007
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabineSamit Hirawat, Jonathan Kolitz, Stuart M Lichtman, et al.
Oncotargets and Therapy|January 22, 2016
PI3K inhibitors as new cancer therapeutics: implications for clinical trial designCristian Massacesi, Emmanuelle Di Tomaso, Patrick Urban, et al.
Muscle & Nerve|November 27, 2009
The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophyCraig M McDonald, Erik K Henricson, Jay J Han, et al.
Journal of Clinical Pharmacology|March 29, 2007
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteersSamit Hirawat, Ellen M Welch, Gary L Elfring, et al.
Clinical Pharmacology in Drug Development|June 17, 2016
Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stress-Regulated Protein TranslationMarla Weetall, Thomas Davis, Gary Elfring, et al.
Pageof 3